{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015713","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.322876+00:00","generated_at":"2026-06-03T11:57:10.323650+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq panel grants Biotricity continued listing subject to milestones by July 29, 2024","bullets":["Panel granted listing continuation after hearing on April 9, 2024.","Conditions include increasing outstanding shares via stock offerings and convertible conversions.","Company must receive shareholder approval for certain actions.","Biotricity must regain compliance with all Nasdaq listing requirements by July 29, 2024.","Previously received delisting notice for MVLS below $35M for 30 consecutive days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015713","json":"https://secwatch.observer/filing/0001493152-24-015713.json","markdown":"https://secwatch.observer/filing/0001493152-24-015713.md","text":"https://secwatch.observer/filing/0001493152-24-015713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224015713/0001493152-24-015713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224015713/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:57:10.323650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"281a50f4740a67b0a4f11371327c51d9e3f84c14","claim":"BIOTRICITY INC. received a nasdaq extension granted notice regarding market value.","evidence_excerpt":"April 23, 2024, Nasdaq notified the Company that the Panel granted its request to continue its listing on Nasdaq, subject to the Company meeting certain milestones including an increase in its outstanding shares of common stock through the issuance of shares of stock in certain stock offerings and upon the conversion of certain convertible securities, the receipt of shareholder approval of certain actions and on or before July 29, 2024, the Company regaining compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224015713/0001493152-24-015713-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"market value"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}